Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | IL1B | P01584 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410243 | 1.00 | CRBN (0.55) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL410700 | 1.00 | CRBN (0.55) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL7284377 | 1.00 | CRBN (0.55) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20075961 | 0.84 | GAA (0.46) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL10074225 | 0.84 | DDB1 (0.61) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL11606116 | 0.83 | DDB1 (0.46) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL986701 | 0.83 | DDB1 (0.46) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL14601082 | 0.80 | DDB1 (0.44) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL14377303 | 0.79 | DDB1 (0.65) | CRBNDDB1IKZF3ALDH1A1CYP1A2 | |
| SCHEMBL15930060 | 0.79 | DDB1 (0.65) | CRBNDDB1IKZF3ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119529118-A | Glutamic acid esterified cellulose, composite fiber, and preparation methods and applications thereof | 武汉纺织大学 | 2025-02-28 | — | — | CN | claimed |
| CN-119306640-A | Gamma-glutamyl transpeptidase detection substrate and preparation method and application thereof | 英科新创(厦门)科技股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| CN-113045446-A | Preparation method of transpeptidase biochemical test reagent substrate | 合肥金锦生物科技有限公司 | 2021-06-29 | — | — | CN | claimed |
| US-8193156-B1 | Dipeptides incorporating selenoamino acids with enhanced bioavailability—synthesis, pharmaceutical and cosmeceutical applications thereof | SAMI LABS LTD | 2012-06-05 | — | — | US | claimed |
| US-8003614-B2 | Dipeptides incorporating selenoamino acids with enhanced bioavailability—synthesis, pharmaceutical and cosmeceutical applications thereof | SAMI LABS LTD (US) | 2011-08-23 | — | — | US | claimed |
| US-20080026017-A1 | Novel Dipeptides incorporating selenoamino acids with enhanced bioavailability- Synthesis, pharmaceutical and cosmeceutical applications thereof | SAMI LABS LIMITED (IN) | 2008-01-31 | — | — | US | claimed |
| EP-1144436-B1 | METHOD FOR PREPARING BICYCLIC COMPOUNDS AND USE OF SAID METHOD FOR PREPARING AN INTERLEUKIN-1(Beta) CONVERSION ENZYME (ICE) INHIBITOR | AVENTIS PHARMA SA (FR) | 2004-04-07 | — | — | EP | claimed |
| US-6512111-B1 | A method for preparing compounds of formula (I) ) wherein cyclization is carried out in a basic medium and in the presence of a phosphonic acid derivative and the use of said method as an intermediate step for preparing a compound | AVENTIS PHARMA S.A. (FR) | 2003-01-28 | — | — | US | claimed |
| EP-0230985-B1 | GAMMA-GLUTAMYL-4-AZOANILIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE DETERMINATION OF GAMMA-GLUTAMYLTRANSFERASE | Roche Diagnostics GmbH (DE) | 1990-08-01 | — | — | EP | claimed |
| JP-55099199-A | — | — | None | — | — | JP | disclosed |
| JP-62260827-A | — | — | None | — | — | JP | disclosed |
| JP-56097260-A | — | — | None | — | — | JP | disclosed |
| JP-1110654-A | — | — | None | — | — | JP | disclosed |
| JP-57050963-A | — | — | None | — | — | JP | disclosed |
| US-4177109-A | BY OXIDATION AND COLOIMETRIC ANALYSIS OF LIBERATED P-PHENYLENEDIAMINE DERIVATIVE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1979-12-04 | — | — | US | disclosed |
| US-4167449-A | Composition and method for determining transferase and protease activity | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1979-09-11 | — | — | US | disclosed |
| US-4076840-A | TREATMENT OF ALCOHOLISM | ASTRA LAKEMEDEL AKTIEBOLAG (SW) | 1978-02-28 | — | — | US | disclosed |
| US-4049702-A | DIAGNOSIS OF LIVER DISEASE BY DETERMINATION OF G-GLUTAMYL-TRANS-PEPTIDASE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1977-09-20 | — | — | US | disclosed |
| US-3986931-A | γ-GLUTAMYL-4-NITROANILIDE COMPOUNDS AND THEIR USE IN DETERMINING γ-GLUTAMYL TRANSPEPTIDASE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-10-19 | — | — | US | disclosed |
| US-3979447-A | DETERMINATION OF G-GLUTAMYLTRANSPEPTIDASE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080026017-A1 | Novel Dipeptides incorporating selenoamino acids with enhanced bioavailability- Synthesis, pharmaceutical and cosmeceutical applications thereof | SCLY, CYP2R1, SPR | CRBN 4149/4885DDB1 1641/4885IKZF3 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.